Dx&Vx
Dx&Vx is a Seoul-based, KOSDAQ-listed Korean biotech operating across diagnostics, microbiome healthcare, novel therapeutics/vaccines, and CDMO services, serving global pharma partners (via licensing), healthcare providers, and consumers (via the Ofmom nutrition brand).
- Company typePublic
- Founded2001
- HeadquartersSeoul, South Korea
- Headcount51–100
- GTM typeB2B and B2C
- OfferingServices
What Dx&Vx does
Dx&Vx is a Seoul-headquartered, KOSDAQ-listed (ticker 180400) diversified biotechnology company founded in 2001 that operates four integrated business verticals: Diagnostics (CLIDEX companion diagnostics, K-Sensor label-free immunosensor, IVD device manufacturing with 3.5M tests/month capacity, and GenomeCheck precision genomics), Novel Therapeutics & Vaccines (mRNA platform, cancer vaccines, antivirals, oral GLP-1 obesity treatments, eye disease therapeutics), Microbiome Healthcare (HMO substitutes, Dx&Vx Therapeutic Supplement Solution, Ofmom family nutrition brand), and Contract Services (CDx Development, CDO, CMO, CSO, K-hub medical data). The company's competitive positioning rests on several proprietary platforms with differentiated claims: a world-first room-temperature ultra-long-term mRNA storage technology licensed from POSTECH (claimed >10-year shelf life without cold chain), the ROP (Recombinant Overlapping Peptide) platform behind OVM-200 cancer vaccine, the LEAD broad-spectrum antiviral peptide platform targeting RNA viruses under 200nm, the Universal NGS self-assembling nano-particle sequencing platform, and LNP extraction technology. Revenue derives from four streams: IVD hardware unit sales (PCR/rapid/ELISA tests), consumer microbiome supplements through the Ofmom brand via e-commerce and convenience store retail (CU Kazakhstan), licensing and co-development royalties from pharma partners (headlined by a $220M mRNA cancer vaccine deal signed in 2025), and CDMO/CDO/CSO professional services.
The company serves a tripartite customer base: global pharmaceutical and biotech firms (via enterprise sales at partnering conferences such as JPM Healthcare Conference, Bio-Europe Spring, ChinaBio Partnering Forum, Arab Health, MEDICA), healthcare providers and diagnostic laboratories, and end consumers in infant nutrition and family wellness. Geographic footprint spans South Korea (HQ and manufacturing), China (Beijing DIWAYSE subsidiary since February 2022), Central Asia (Kazakhstan retail), Southeast Asia (Malaysia), Mongolia, and the UK (Oxford Vacmedix subsidiary for European clinical operations). Revenue was approximately 20.3 billion KRW (~$15M USD) in 2025 with consistently negative operating income and net losses, reflecting heavy R&D investment against a still-modest commercial revenue base—balanced by 85 billion KRW in ARPA-H government funding for room-temperature mRNA vaccine development and 29 billion KRW for Disease X antiviral development over coming years.
Dx&Vx firmographics
Firmographics- Name
- Dx&Vx
- Legal name
- DX&VX Corporation
- Website
- https://dxvx.com
- Company type
- Public
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Dx&Vx is a Seoul-based, KOSDAQ-listed Korean biotech operating across diagnostics, microbiome healthcare, novel therapeutics/vaccines, and CDMO services, serving global pharma partners (via licensing), healthcare providers, and consumers (via the Ofmom nutrition brand).
- Ownership category
- akta.pro rank
Dx&Vx industry classification
Industry- Product category
- Biopharmaceuticals and precision diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Medical and Diagnostic Laboratories (62151)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)
- akta.pro secondary industries
- Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy) (HLAAAMAB), Companion Diagnostics (CDx) & Precision Medicine IVD (HLAHAAAJ), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
Keywords
Where Dx&Vx is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
Dx&Vx business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Diagnostics and IVD Products: Sales of diagnostic products including CLIDEX companion diagnostics, K-Sensor label-free immunosensor, PCR tests, rapid tests, ELISA tests, and precision diagnostics services (GenomeCheck). Production capacity of 3,500,000 tests/month.
- Healthcare and Supplement Products: Sales of microbiome-based health supplements including Dx&Vx Therapeutic Supplement Solution, Ofmom product line (probiotics, oat drinks, formulas), and various health functional foods through e-commerce and retail channels.
- New Drug Development and Licensing: Revenue from licensing out drug pipeline technologies including mRNA platforms, cancer vaccines, obesity treatments, and antiviral platforms to global pharmaceutical companies. USD 220 million co-development and license agreement signed for mRNA cancer vaccine.
- CDMO/CDO/CSO Services: Contract Development and Manufacturing services including Dx Health Check, CDx Development Service, Medical Data (K-hub), CDO, CMO, and CSO services for pharmaceutical and biotech clients.
- HMO Products: Human Milk Oligosaccharide substitute products for infant nutrition and microbiome health applications.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | In vitro diagnostic products with production capacity of 3,500,000 tests/month |
| Unit Pricing | Pay-as-you-go | Health functional food and supplement products through e-commerce and retail |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels6 records
Dx&Vx product offering
Product offeringCore offering
Dx&Vx develops and commercializes an integrated biotechnology stack consisting of precision companion diagnostics (CLIDEX, K-Sensor, GenomeCheck, NGS panels, IVD devices), a proprietary mRNA and peptide drug pipeline (cancer vaccines, COVID-19 vaccines/antivirals, GLP-1 obesity therapeutics, dry-eye treatment), and microbiome-based healthcare products (HMO ingredients, Ofmom infant nutrition, therapeutic supplements). It also offers CDO/CMO/CSO contract development services and licenses its proprietary mRNA storage, ROP, LEAD peptide, and SynterAct AI platforms to global pharmaceutical partners.
Product overview
Dx&Vx is a diversified biotech company operating across four main business areas: Diagnostics (CLIDEX companion diagnostics, K-Sensor label-free immunosensor, in vitro diagnostic device development), New Drugs/Vaccines (mRNA platform, universal COVID vaccine, OVM-200 cancer vaccine, mRNA anti-cancer vaccine, GLP-1 oral obesity treatment, peptide obesity treatment, dry eye treatment), Microbiome/Healthcare (HMO, metabolism care, immune care, Dx&Vx Therapeutic Supplement Solution, Ofmom family nutrition brand), and Contract Services (CDx development, CDO, CMO, CSO, Dx Health Check, Medical Data K-hub). The company also operates the mRNA Platform (ultra-long-term room temperature storage, world's first and only), Universal NGS Platform, and LNP Extraction Platform as core technology enablers underpinning multiple pipeline products.
Differentiator
Problem solved
Functional benefit
Brands
- Ofmom: Family nutrition brand offering probiotic products, oat beverages, and nutritional supplements for infants, toddlers, and 2030 women, based on European patent SynterAct Technology.
- CLIDEX
- Dx&Vx Therapeutic Supplement Solution
- GenomeCheck
- K-Sensor
Products and services
- CLIDEX Companion Diagnostics CLIDEX is an AI-based companion diagnostics platform that pairs patients with appropriate therapeutics, supporting precision medicine partnerships with pharmaceutical companies.
- K-Sensor Label-Free Immunosensor K-Sensor is a proprietary label-free immunosensor platform used for diagnostic detection, enabling rapid and sensitive biomarker measurement without labels.
- Dx Health Check Dx Health Check is a diagnostic health check service leveraging Dx&Vx's precision diagnostics portfolio for clinical and consumer health screening.
- CDx Development Service Companion Diagnostic Development Service offers end-to-end CDx development for pharmaceutical and diagnostic partners, supporting drug-diagnostic pairing and regulatory submission.
- In Vitro Diagnostic Device Development IVD device development service delivers in-vitro diagnostic device engineering, validation, and commercialization support to diagnostic manufacturers and clinical laboratories.
- CDO (Contract Development Organization) Service CDO service provides outsourced drug development to biotech and pharmaceutical clients, leveraging Dx&Vx's mRNA, peptide, and vaccine platforms.
- CMO (Contract Manufacturing Organization) Service CMO service provides outsourced manufacturing for biotech and pharmaceutical clients, supporting production of vaccines, therapeutics, and diagnostics.
- CSO (Contract Sales Organization) Service CSO service provides outsourced sales and commercialization support for healthcare, biotech, and pharmaceutical clients, including medical data support via K-hub.
- K-hub Medical Data Platform K-hub is Dx&Vx's integrated medical data platform providing patient, clinical, and outcomes data to support companion diagnostic development, contract sales operations, and clinical research.
- Ofmom Infant Nutrition Ofmom is Dx&Vx's consumer infant nutrition brand, providing microbiome-supporting formula and nutrition products for parents of infants and young children.
- HMO (Human Milk Oligosaccharides) Products HMO products are Human Milk Oligosaccharide-based microbiome nutrition offerings distributed in China through the Beijing DIWAYSE subsidiary and globally as ingredients.
- Dx&Vx Therapeutic Supplement Solution Dx&Vx Therapeutic Supplement Solution is a consumer supplement product line addressing microbiome, metabolic, immune, menstrual, and eye health needs.
- Metabolism Care Supplement Metabolism Care is a consumer supplement product supporting metabolic health within Dx&Vx's therapeutic supplement portfolio.
- Immune Care Supplement Immune Care is a consumer supplement product supporting immune health within Dx&Vx's therapeutic supplement portfolio.
- mRNA Drug Platform (Room-Temperature Stable) Dx&Vx's proprietary mRNA drug platform features room-temperature storage at 5°C–25°C without ultra-cold chain, supporting vaccine and therapeutic development for global pharmaceutical licensing partners.
- Universal COVID-19 Vaccine (DX-DRG-B05) Universal COVID-19 Vaccine (DX-DRG-B05) is a universal-strain COVID-19 vaccine asset in Dx&Vx's proprietary mRNA pipeline.
- Universal COVID-19 Anti-viral (DX-DRG-B00) Universal COVID-19 Anti-viral (DX-DRG-B00) is a LEAD peptide-based broad-spectrum antiviral targeting COVID-19 in Dx&Vx's pipeline.
- Microbiome Bacteria Vaccine (DX-DRG-M01) Microbiome Bacteria Vaccine (DX-DRG-M01) is a microbiome-based vaccine candidate within Dx&Vx's therapeutic pipeline.
- OVM-200 Cancer Vaccine (DX-DRG-B02) OVM-200 Cancer Vaccine (DX-DRG-B02) is a cancer vaccine candidate built on Dx&Vx's proprietary ROP (Radiotherapy-Operative Polymer) platform.
- mRNA Anti-cancer Vaccine (DX-DRG-R02) mRNA Anti-cancer Vaccine (DX-DRG-R02) is a circular/linear mRNA cancer vaccine candidate in Dx&Vx's oncology pipeline.
- Therapeutic Antibody (DX-DRG-B01) Therapeutic Antibody (DX-DRG-B01) is a therapeutic antibody candidate within Dx&Vx's biopharmaceutical pipeline.
- GLP-1 Oral Obesity Treatment (DX-DRG-C01) GLP-1 Oral Obesity Treatment (DX-DRG-C01) is an oral GLP-1 receptor agonist obesity candidate within Dx&Vx's metabolic pipeline.
- Peptide Obesity Treatment (DX-DRG-C02) Peptide Obesity Treatment (DX-DRG-C02) is a peptide-based obesity therapeutic candidate within Dx&Vx's metabolic pipeline.
- Dry Eye Disease Treatment (AVI-4015) Dry Eye Disease Treatment (AVI-4015) is a therapeutic candidate for dry eye disease within Dx&Vx's pipeline.
Quantifiable outcome
- mRNA stability at 40°C for 2 weeks demonstrated
- +4 more outcomes
Companies that use Dx&Vx
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
Dx&Vx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature10 records
Dx&Vx partnerships and signals
Strategic signalScale indicators12 records
Recent moves7 records
Expansion highlights6 records
Dx&Vx competitors and assessment
Company assessmentDirect peers
- Macrogen: Seoul-based genomics and precision diagnostics company offering NGS services, molecular diagnostics, and CDMO services. Most direct Korean comparable given overlap in genomic sequencing, IVD, and clinical development capabilities, and serves as the source of Dx&Vx's newly recruited diagnostic division head.
- SK Bioscience: Korean vaccine developer and CDMO with infectious disease pipeline, mRNA manufacturing capabilities, and global pharma partnerships. Comparable as a Korean-headquartered biotech pursuing mRNA and viral vaccines with both licensing-out and co-development business models.
- Genexine: Korean clinical-stage biotech developing gene therapies, vaccines, and antibody therapeutics. Comparable platform-stage biotech focused on immuno-oncology and vaccines, recently served as the source for Dx&Vx's gene therapy/vaccine recruitment.
- CureVac: German mRNA technology company developing vaccines and therapeutics with emphasis on optimized mRNA constructs. Closest direct technology peer to Dx&Vx's mRNA platform work, including comparable focus on improving mRNA stability and delivery.
- Seres Therapeutics: U.S. microbiome therapeutics company developing defined bacterial consortia for serious diseases. Closest direct peer to Dx&Vx's microbiome-based supplements and respiratory vaccine programs, including comparable focus on SynterAct-style bacterial viability technology.
- Oxford Vacmedix: Wholly-owned Dx&Vx subsidiary developing the ROP-based OVM-200 cancer vaccine. Included as a peer reference point since it is the operational entity driving Dx&Vx's lead oncology asset and historically operated as an independent UK biotech prior to acquisition.
Broad incumbents
- Moderna: Global mRNA platform leader with commercial COVID vaccine, oncology pipeline, and extensive manufacturing infrastructure. Establishes the competitive ceiling in mRNA technology and serves as the benchmark for technology valuations in licensing deals involving Dx&Vx's mRNA assets.
- Celltrion: Korean biosimilars and biologics leader with extensive CDMO capacity, global commercialization, and pipeline diversification. Comparable as a Korean-listed biotech scaling internationally, though substantially larger and more established than Dx&Vx.
- Myriad Genetics: U.S. precision medicine and companion diagnostics company offering genetic tests for therapy selection. Comparable business model to Dx&Vx's CLIDEX platform in leveraging genomic data and clinical evidence to support pharmaceutical partner decision-making.
- BioNTech: Global mRNA immunotherapy leader with commercial COVID vaccine and extensive oncology pipeline including individualized neoantigen vaccines. Key competitor in cancer vaccine and mRNA technology licensing markets, representing the established standard Dx&Vx must differentiate against.
Market position
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
Dx&Vx social profiles
Digital presenceDx&Vx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dx&Vx leadership team
Management profileNumber of profiles
Profiles14 records
Dx&Vx subsidiaries and ownership
Company hierarchySubsidiaries2 records
Dx&Vx funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dx&Vx M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dx&Vx
What does Dx&Vx do?
Dx&Vx develops and commercializes an integrated biotechnology stack consisting of precision companion diagnostics (CLIDEX, K-Sensor, GenomeCheck, NGS panels, IVD devices), a proprietary mRNA and peptide drug pipeline (cancer vaccines, COVID-19 vaccines/antivirals, GLP-1 obesity therapeutics, dry-eye treatment), and microbiome-based healthcare products (HMO ingredients, Ofmom infant nutrition, therapeutic supplements). It also offers CDO/CMO/CSO contract development services and licenses its proprietary mRNA storage, ROP, LEAD peptide, and SynterAct AI platforms to global pharmaceutical partners.
Is Dx&Vx a public or private company?
Dx&Vx is a public company. It is classified as public and is currently operating.
When was Dx&Vx founded?
Dx&Vx was founded in 2001. It employs 51 to 100 people.
Where is Dx&Vx based?
Dx&Vx is headquartered in Seoul, South Korea, in the Asia region.
How does Dx&Vx make money?
Five revenue lines are on record. Diagnostics and IVD Products are the primary driver. The others are healthcare and Supplement Products, new Drug Development and Licensing, CDMO/CDO/CSO Services and HMO Products.
Who are Dx&Vx's main competitors?
Direct peers on record are Macrogen, SK Bioscience, Genexine, CureVac, Seres Therapeutics and Oxford Vacmedix. Broad incumbents are Moderna, Celltrion, Myriad Genetics and BioNTech.
Does Dx&Vx have an API?
No public API is recorded for Dx&Vx.
What industry is Dx&Vx in?
Dx&Vx's product category is Biopharmaceuticals and precision diagnostics. Its primary akta.pro industry code is HLAGAGAC, mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA), with a secondary code of HLAAAMAB, Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy). Its NAICS code is 325413 and its SIC code is 2835.